Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669493 | 1.00 | MCHR1 (1.00) | MCHR1NPC1TP53NFKB1RAB9A | |
| SCHEMBL29391945 | 1.00 | MCHR1 (1.00) | MCHR1NPC1TP53NFKB1RAB9A | |
| Hydrochloric Acid SCHEMBL5582925 | 0.99 | MCHR1 (0.98) | MCHR1NPC1TP53NFKB1RAB9A | |
| SCHEMBL5582838 | 0.94 | MCHR1 (0.89) | MCHR1NPC1TP53NFKB1RAB9A | |
| SCHEMBL14454781 | 0.91 | MCHR1 (1.00) | MCHR1ITGB3ITGA2B | |
| SCHEMBL14454794 | 0.91 | MCHR1 (1.00) | MCHR1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL5582601 | 0.91 | MCHR1 (1.00) | MCHR1ITGB3ITGA2B | |
| SCHEMBL4621859 | 0.91 | MCHR1 (1.00) | MCHR1ITGB3ITGA2B | |
| SCHEMBL14454784 | 0.91 | MCHR1 (0.85) | MCHR1ITGB3ITGA2B | |
| SCHEMBL5582618 | 0.91 | MCHR1 (0.85) | MCHR1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | claimed |
| CN-116403066-B | Model training method, image quality evaluation device and storage medium | 北京达佳互联信息技术有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-118229854-A | Animation generation method, device, electronic equipment and storage medium | 杭州弹指宇宙科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117952493-A | Logistics data analysis method and device, electronic equipment and storage medium | 上海乾臻信息科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117911175-A | Early warning method and device for settlement website, electronic equipment and storage medium | 上海东普信息科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-116403066-A | Model training method, image quality evaluation device and storage medium | 北京达佳互联信息技术有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-112053439-B | Method, device and equipment for determining instance attribute information in image and storage medium | 腾讯科技（深圳）有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115203208-A | Value range table matching method, device, equipment and storage medium | 腾讯科技（深圳）有限公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-2203416-B1 | (CARBOXY ALKYLENE-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINES | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-8828994-B2 | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| WO-2007093365-A2 | NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| WO-2007045393-A1 | CARBAMOYLBENZOTRIAZOLE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007039177-A2 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039178-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039176-A1 | DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039173-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885NPC1 1085/4885TP53 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.